Bayer Stock
Bayer Stock

Investor Information

In the third quarter of 2008 the stock market was dominated by the effects of the international financial crisis, with the DAX down nearly 8 percent on the period. In this volatile environment, Bayer stock largely held its own, moving more or less laterally (–1.6 percent). The relative strength of our stock was also evident over the nine-month period. Although Bayer stock closed at €51.80 on September 30, 2008, down 17.2 percent from the end of 2007, giving a performance of minus 15.1 percent, the DAX lost 27.7 percent in the same period, closing at 5,831 points. The European reference index EURO STOXX 50 suffered comparably heavy losses, closing the third quarter at 4,615 points, down 28.4 percent from the beginning of the year.
 
With effect from September 22, 2008, Bayer stock is included in the Dow Jones STOXX 50, a European blue chip index comprising the top 50 stocks from 17 western European countries.

At the end of September, Bayer hosted the “Meet Management” conference in Lever­kusen for the third time. Some 90 investors and analysts accepted the company’s invitation to participate in group discussions with members of the management boards of Bayer AG and the subgroups. These talks focused on corporate strategy, developments in key markets, the effects of the financial crisis and the candidates in the pharmaceutical research pipeline.
Bayer Stock Key Data  3rd
Quarter
2007
3rd
Quarter
2008
First Nine
Months
2007
First Nine
Months
2008
High for the period 58.5657.5358.5665.68
Low for the period 50.3351.8040.2045.90
Average daily share turnover on
German stock exchanges
million6.04.95.95.5
  Sept. 30,
2007
Sept. 30,
2008
Dec. 31,
2007
Change
Sept. 30, 2008/
Dec. 31, 2007
%
Share price 55.8251.8062.53-17.2
Market capitalization € million 42,66539,59347,794-17.2
Stockholders’ equity as per balance sheets € million 17,00818,31016,821+8.9
Number of shares entitled to the dividend million764.34764.34764.340.0
      
DAX 7,8625,8318,067-27.7
Performance over the Past Twelve Months
(indexed; 100 = Xetra closing price on September 30, 2007)
Performance over the Past Twelve Months
Earnings per share according to IFRS are affected by the purchase price allocation for Schering, Berlin, Germany, and other special factors. To enhance comparability, we also determine core net income from continuing operations after elimination of the amorti­zation of intangible assets, asset write-downs (including any impairment losses), special items in EBITDA including the related tax effects, and one-time tax income or expense.
 
The calculation of earnings per share in accordance with the International Financial Reporting Standards (IFRS) is explained in the notes to the consolidated financial statements. Adjusted core net income, core earnings per share and core EBIT are not defined in the IFRS. Therefore they should be regarded as supplementary information rather than stand-alone indicators.
Calculation of Core EBIT
and Core Earnings per Share
3rd
Quarter
2007
3rd
Quarter
2008
First Nine
Months
2007
First Nine
Months
2008
€ million     
EBIT as per income statement6776842,7693,132
Amortization and write-downs of intangible assets 4793851,0971,170
Write-downs of property, plant and equipment 938663
Special items (other than write-downs) 120159570411
Core EBIT1,2851,2314,5224,776
Non-operating result (as per income statement) (266)(276)(741)(813)
Income taxes (as per income statement) 769(133)221(701)
One-time tax income* (911)0(911)0
Tax adjustment (234)(151)(617)(484)
Income after taxes attributable to minority interest
(as per income statement)
(3)(1)(1)(8)
Core net income from continuing operations6406702,4732,770
Financing expenses for the mandatory convertible bond,
net of tax effects
25287384
Adjusted core net income6656982,5462,854
     
Shares
    
Weighted average number of issued
ordinary shares

764,341,920764,341,920764,341,920764,341,920
Potential shares to be issued upon conversion of the mandatory convertible bond
59,585,49360,040,82359,558,60659,843,529
Adjusted weighted average total number
of issued and potential ordinary shares
823,927,413824,382,743823,900,526824,185,449
Core earnings per share from
continuing operations (€)
0.810.853.093.46
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
top
Print page
Search
Search
Advanced Search
Download Center
 
Links
Annual Report 2007
 
Financial Reports
 
Comparison
Services
Order print version
 
Event Reminder
 
Press Newsletter
 
Would you like to be kept informed about new financial reports from Bayer?
 
SMS Service
Calendar
Investor Conference Call
Info
Notes on our information package and all services